Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7240-7248

  Karaiskos, Ilias ^a   Friberg, Lena E ^b   Pontikis, Konstantinos ^c   Ioannidis, Konstantinos ^a   Tsagkari, Vasiliki ^c   Galani, Lamprini ^a   Kostakou, Eirini ^c   Baziaka, Fotini ^a   Paskalis, Charalambos ^a   Koutsoukou, Antonia ^c   Giamarellou, Helen ^a  

^a IASO GENERAL HOSPITAL   (Greece)

^b UPPSALA UNIVERSITY   (Sweden)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; COLISTIN; ANTIINFECTIVE AGENT; COLISTINMETHANESULFONIC ACID; CREATININE;

ADULT; AGED; ARTICLE; BACTERIAL STRAIN; BLOOD SAMPLING; CLINICAL ARTICLE; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; KIDNEY INJURY; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; TANDEM MASS SPECTROMETRY; VERY ELDERLY; VOLUME OF DISTRIBUTION; YOUNG ADULT; ACUTE KIDNEY FAILURE; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CRITICAL ILLNESS; DRUG ADMINISTRATION; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; GROWTH, DEVELOPMENT AND AGING; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; PATHOLOGY; STATISTICAL MODEL;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, LIQUID; COLISTIN; CREATININE; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, STATISTICAL; TANDEM MASS SPECTROMETRY;

EID: 84954478107     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00554-15     Document Type: Article

References (28)

1. Karaiskos I, Giamarellou H. 2014. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 15:1351-1370. http://dx.doi.org/10.1517/14656566.2014.914172.
2. World Health Organization (WHO). 2011. Antimicrobial resistance: no action today, no cure tomorrow. WHO Press, Geneva, Switzerland. http: //www.who.int/world-health-day/2011/en/index.html.
3. Boucher HW, Talbot GH, Bradley JS. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
4. Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:1953-1958. http://dx.doi.org/10.1128/AAC.00035-06.
5. Jansson B, Karvanen M, Cars O, Plachouras D, Friberg LE. 2009. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J Pharm Biomed Anal 49:760-767. http://dx.doi.org/10.1016/j.jpba.2008.12.016.
6. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gramnegative bacteria. Antimicrob Agents Chemother 53:3430-3436. http: //dx.doi.org/10.1128/AAC.01361-08.
7. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE. 2012. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56:4241-4249. http://dx.doi.org/10.1128/AAC.06426-11.
8. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284-3294. http://dx.doi.org /10.1128/AAC.01733-10.
9. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement, M100-S23. CLSI, Wayne, PA.
10. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
11. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative Workgroup. 2004. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204-R212. http://dx.doi.org/10.1186/cc2872.
12. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentine J. 2002. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 46:3304-3307. http://dx.doi.org/10.1128/AAC.46.10.3304-3307.2002.
13. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481-504. http://dx.doi.org/10.1023/A:1012299115260.
14. Keizer RJ, Karlsson MO, Hooker A. 2013. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol 2:e50. http://dx.doi.org/10.1038/psp.2013.24.
15. Ito K, Murphy D. 2013. Application of ggplot2 to pharmacometric graphics. CPT Pharmacometrics Syst Pharmacol 2:e79. http://dx.doi.org /10.1038/psp.2013.56.
16. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589-1596. http://dx.doi.org/10.1097/01.CCM.0000217961.75225.E9.
17. Kumar A. 2014. An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy. Virulence 5:80-97. http://dx.doi.org/10.4161/viru.26913.
18. Grégoire N, Mimoz O, Mégarbane B, Comets E, Chatelier D, Lasocki S, Gauzit R, Balayn D, Gobin P, Marchand S, Couet W. 2014. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Antimicrob Agents Chemother 58: 7324-7330. http://dx.doi.org/10.1128/AAC.03508-14.
19. He H, Li JC, Nation RL, Jacob J, Chen G, Lee HJ, Tsuji BT, Thompson PE, Roberts K, Velkov T, Li J. 2013. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J Antimicrob Chemother 68:2311-2317. http://dx.doi.org/10.1093/jac/dkt207.
20. Nation RL, Velkov T, Li J. 2014. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 59:88-94. http://dx.doi.org/10.1093 /cid/ciu213.
21. Couet W, Grégoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, Mimoz O. 2011. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 89:875-879. http://dx.doi.org/10.1038/clpt.2011.48.
22. Roberts JA, Lipman J. 2009. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840-851. http://dx.doi.org/10.1097 /CCM.0b013e3181961bff.
23. Nation RL, Li J, Turnidge JD. 2013. The urgent need for clear and accurate information on the polymyxins. Clin Infect Dis 57:1656-1657. http://dx.doi.org/10.1093/cid/cit522.
24. Theuretzbacher U. 2014. Product information for parenteral colistin varies substantially across Europe. J Antimicrob Chemother 69:1987-1992. http://dx.doi.org/10.1093/jac/dku064.
25. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS. 2011. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53:879-884. http://dx.doi.org/10.1093/cid/cir611.
26. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. 2013. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 57:1300-1303. http://dx.doi.org/10.1093/cid/cit453.
27. Justo JA, Bosso JA. 2015. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy 35:28-33. http://dx.doi.org/10.1002/phar.1493.
28. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N. 2012. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 54:1720-1726. http://dx.doi.org/10.1093/cid/cis286.